ATLAB Pharma develops antibody-targeted radiotherapy for cancer treatment.
Radioimmunotherapy is a tumor-specific delivery system using monoclonal antibodies conjugated to radioisotopes (radio-antibodies) to target radiation to cancer cells wherever they have disseminated in the body, thus expanding the well-proven efficacy of radiotherapy from localized tumors to metastatic cancers.
ATLAB Pharma is at the forefront of developing safe and efficient radio-antibodies based on new generation therapeutic radioisotopes Lutetium-177 and Astatine-211.
ATLAB Pharma lead drug candidate, ATL101, has been shown to have a favorable safety profile and anti-tumor activity in Phase I and Phase II clinical trials in patients with castrate-resistant prostate cancer.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- atlab-pharma.com
- Keywords
- Copenhagen.
Atlab Pharma Questions
Atlab Pharma's website is atlab-pharma.com
Atlab Pharma's LinkedIn profile is https://fr.linkedin.com/company/atlab-pharma
Atlab Pharma has
3 employees.
View email and phone details for 3
employees at Atlab Pharma.
Atlab Pharma's industry is
Biotechnology Research
Atlab Pharma's top competitors are
Atlanchim Pharma,
Xenothera,
Janvier Group Biosciences,
Atlab,
Fédération Française Des Industries De Santé - Fefis,
Ogd2 Pharma,
Physiogenex,
Imavita,
Remora Biotech,
Atlanthera.
Atlab Pharma's categories are Biotechnology Research
Atlab Pharma's founding year is 2008
